IDH1 and acute myeloid leukemia: Advanced by basic and translational research, especially through large scale genomic analysis to understand the molecular landscape of AML, the development of targeted therapies, such as targeting fms-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations, the treatment of AML landscape changed significantly with FDA approvals for several new drugs in the past several years.